<DOC>
	<DOC>NCT02862535</DOC>
	<brief_summary>The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with S-1 and cisplatin chemotherapy in Japanese participants with inoperable advanced or recurrent gastric or recurrent gastroesophageal junction (GEJ) adenocarcinoma.</brief_summary>
	<brief_title>Andecaliximab as Monotherapy and in Combination With Chemotherapy in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Key Must have been born in Japan and must not have lived outside of Japan for a period &gt; 1 year in the 5 years prior to Day 1 Must be able to trace their maternal and paternal ancestry of parents and grandparents as ethnically Japanese Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the GEJ) or relapsed gastric adenocarcinoma Human Epidermal Growth Factor Receptor 2 (HER2)negative tumor (primary tumor or metastatic lesion) Monotherapy cohort: Prior antitumor therapy or cytotoxic chemotherapy is acceptable. Individuals who are not eligible to receive standard treatments should enroll on the study. Combination therapy cohort: Prior antitumor therapy or cytotoxic chemotherapy is not acceptable. Individuals must be chemonaive in the metastatic setting. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 Adequate baseline organ function (within 28 days prior to Day 1) Coagulation: International Normalized Ratio (INR) ≤ 1.6 (unless receiving anticoagulation therapy). For females of childbearing potential, willingness to use a protocolrecommended method of contraception from the screening visit throughout the study treatment period and for 90 days following the last dose of andecaliximab For males of childbearing potential having intercourse with females of childbearing potential, willingness to use a protocolrecommended method of contraception from the start of andecaliximab, throughout the study treatment period, and for 90 days following the last dose of andecaliximab Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions Key History or evidence of a clinically significant disorder, condition, or disease that, in the opinion of the investigator and medical monitor would pose a risk to participant safety or interfere with the study evaluations, procedures, or completion Pregnant or lactating. Enrollment of lactating females after discontinuation of breastfeeding is not acceptable. Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids Myocardial infarction, symptomatic congestive heart failure (New York Heart Association Classification &gt; Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of Day 1 Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires IV antibiotics Individuals known to be positive for human immunodeficiency virus (HIV), hepatitis C infection (per local standard diagnostic criteria), or acute or chronic hepatitis B infection (per local standard diagnostic criteria) NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>